王學富，教授，博士生導師

研究方向：

（1）腫瘤免疫逃逸機制與免疫治療

（2）肝臟炎癥損傷機制與關鍵靶標

電子郵箱：wangxuefu@ahmu.edu.cn

教育經(jīng)歷：

(1) 2007/09-2012/11， 中國科學技術(shù)大學，生命科學學院，博士（碩博連讀）

(2) 2003/09-2007/06， 安徽大學，生命科學學院，學士

工作經(jīng)歷：

(1) 2022/10-至今，安徽醫(yī)科大學，藥學科學學院（原藥學院），教授

(2) 2016/09-2022/09，安徽醫(yī)科大學，藥學院，副教授

(3) 2015/08-2016/09，安徽醫(yī)科大學，藥學院，校聘副教授

(4) 2012/12-2015/07，中國科學技術(shù)大學，生命科學學院，博士后

學術(shù)榮譽：

(1) 2021/01安徽省優(yōu)青

(2) 2023/09安徽省高校杰青

學術(shù)兼職：

(1) 2023/03中國免疫學會青年工作委員會常務委員

(2) 2023/12中國藥理學會抗炎免疫藥理專業(yè)委員會委員

(3) 2024/01合肥市藥學會副理事長

主持課題項目情況：

（1）國家自然科學基金委員會，面上項目，82371756，GPR35促進膽固醇酯化抑制CD8+T細胞功能介導免疫逃逸的機制研究，2024/1-2027/12，主持

（2）國家自然科學基金委員會，面上項目，82070608，孤兒受體GPR35通過代謝重編程調(diào)控巨噬細胞極化發(fā)揮抗藥物性肝損傷作用，2021/01-2024/12，主持

（3）國家自然科學基金委員會，面上項目，31872741，犬尿喹啉酸對NLRP3炎癥小體活化及相關炎癥疾病的調(diào)控作用與機制研究，2019/01-2022/12，主持

發(fā)表論文情況：

(1) Wang H#, Li F#, Feng Y#, Ma W, Li Y, Zhao X, Wu J, Shi C, Zong L, Li J*, Cong J*, Wang X*. Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells. Int Immunopharmacol. 2025 Feb 6; 147:113971.

(2) Zhao X, Li F, Cheng C, Bi M, Li J*, Cong J*, Wang X*. Social isolation promotes tumor immune evasion via β2-adrenergic receptor. Brain Behav Immun. 2025 Jan; 123:607-618.

(3) Yan J#, Wang H#, Zhao X#, Tao L*, Wang X*, Yin J*. Polymorphic Supramolecular Therapeutic Platforms with Precise Dye/Drug Ratio to Perform Synergistic Chemo-Photo Anti-Tumor Therapy and Long-Term Immune Protection. Adv Healthc Mater. 2024 Oct 7: e2402907.

(4) Yan J#, Jiang W#, Kang G#, Li Q, Tao L*, Wang X*, Yin J*. Synergistic chemo-photo anticancer therapy by using reversible Diels-Alder dynamic covalent bond mediated polyprodrug amphiphiles and immunoactivation investigation. Biomater Sci. 2023 Aug 22;11(17):5819-5830.

(5) Guangwei Yang#, Longxiang Tao#, Guijie Kang#, Jinhao Yan, Kewu He*, Xuefu Wang*, and Jun Yin*. Construction of Actively Targeted and High Drug Content Polyprodrug Amphiphiles to Perform Synergistic Chemo–Photo-Anti-Tumor Therapy and Immune-Activated Investigation. Chem. Mater. 2023 June 13;2023, 35, 12, 4831-4844.

(6) Kang G#, Zhao X#, Sun J#, Cheng C, Wang C, Tao L, Zong L, Yin W, Cong J*, Li J*, Wang X*. A2AR limits IL-15-induced generation of CD39+ NK cells with high cytotoxicity. Int Immunopharmacol. 2023 Jan; 114:109567.

(7) Tao L#, Wang S#, Kang G#, Jiang S, Yin W, Zong L, Li J, Wang X*. PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma. Oncoimmunology. 2021 Nov 9;10(1):2002068.

(8) Yang L#, Feng Y#, Wang S#, Jiang S, Tao L*, Li J*, Wang X*. Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia. Int Immunopharmacol. 2021 Jul 14; 99:107965.

(9) Bi J*, Wang X*. Molecular Regulation of NK Cell Maturation.  Front Immunol. 2020 Aug 11; 11:1945

(10) Tao L#, Wang S#, Yang L, Jiang L, Li J*, Wang X*. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma. Clin. Exp. Immunol. 2020 Aug;201(2)

(11) Wang X, Sun R, Hao X, Lian ZX, Wei H, Tian Z. IL-17 constrains natural killer cell activity by restraining IL-15-driven cell maturation via SOCS3. Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17409-17418.

(12) Wei X#, Yin F#, Wu M#, Xie Q, Zhao X, Zhu C, Xie R, Chen C, Liu M, Wang X, Ren R, Kang G, Zhu C, Cong J, Wang H*, Wang X*. G protein-coupled receptor 35 attenuates nonalcoholic steatohepatitis by reprogramming cholesterol homeostasis in hepatocytes. Acta Pharm Sin B. 2023 Mar;13(3):1128-1144.

(13) Sun T#, Xie R#, He H#, Xie Q, Zhao X, Kang G, Cheng C, Yin W, Cong J, Li J*, Wang X*. Kynurenic acid ameliorates NLRP3 inflammasome activation by blocking calcium mobilization via GPR35. Front Immunol. 2022 Oct 13; 13:1019365.

(14) Yin F#, Wu MM#, Wei XL#, Ren RX, Liu MH, Chen CQ, Yang L, Xie RQ, Jiang SY, Wang XF*, Wang H*. Hepatic NCoR1 deletion exacerbates alcohol-induced liver injury in mice by promoting CCL2-mediated monocyte-derived macrophage infiltration.  Acta Pharmacol Sin. 2022 Sep;43(9):2351-2361.

(15) Wang X, Sun R*, Wei H, Tian Z*. High-mobility group box 1 (HMGB1)-Toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: Interaction of γδ T cells with macrophages. Hepatology. 2013 Jan;57(1):373-84.